Sionna Stock 144% This Year: Is the Biotech a Buy Now?
Sionna Therapeutics has surged 144% over the past year, drawing attention from growth-minded investors. This article ...
Timing matters: knowing when to review your budget helps you adjust before problems arise. This overview covers effective review moments.
17,852 articlesSionna Therapeutics has surged 144% over the past year, drawing attention from growth-minded investors. This article ...
A 73-year-old’s first required minimum distribution triggered a dramatic tax shift, illustrating how IRAs and Social ...
If the Fed delivers a single rate move in 2026, bond ETFs could react in surprising ways. This article explains what ...
As institutional buyers step into Openlane, individual investors gain a front-row seat to a digitized used-vehicle ma...
As Taysha prepares to share Q4 2025 results, investors search for clarity on cash runway, pipeline progress, and futu...
A director at Arteris disclosed disposing over 20,000 shares, split between a gift and an open-market sale. Here’s ho...
When NVIDIA reports earnings on Feb. 25, investors will scan every line for AI demand signals, margin trends, and gui...
SkyWater Technology just posted a record revenue figure, but the CFO sold about $2.5 million worth of stock. This art...
Insider sales in biotech can spark questions about a company’s future. This guide breaks down what to watch, how to r...
When Apple moves more of its production to the U.S., investors often respond quickly. This article explains why apple...
A four-year tax window under SECURE 2.0 lets workers aged 60-63 contribute up to $11,250 a year to a 401(K). Surgeons...
New 2026 guidance shows high earners with million+ 401(k)s can still build tax-free Roth assets through after-tax con...